Table 2.
Mean per cent change in serum TTR and RBP4 levels from baseline to 2 weeks after the last dose in the multiple dose groups
| AKCEA‐TTR‐LRx | ||||
|---|---|---|---|---|
| % change from baseline | Placebo | 45 mg | 60 mg | 90 mg |
| TTR | ||||
| n | 6 | 10 | 10 | 10 |
| Mean (SD) | −5.9 (14.0) | −85.7 (8.0) | −90.5 (7.4) | −93.8 (3.4) |
| Min, Max | −28.5, 10.0 | −93.5, −71.7 | −97.2, −71.8 | −98.4, −87.0 |
| P‐value [A] | <0.001 | <0.001 | <0.001 | |
| RBP4 | ||||
| n | 6 | 10 | 10 | 10 |
| Mean (SD) | −0.2 (13.3) | −77.3 (12.5) | −79.2 (5.5) | −84.0 (4.6) |
| Min, Max | −15.5, 21.4 | −89.7, −51.1 | −89.0, −70.2 | −90.2, −74.6 |
| P‐value [T] | 0.006 | 0.006 | 0.006 | |
[A] ANOVA test P‐value, [T] Wilcoxon rank sum t approximation test two‐sided P‐value. Max, maximum; Min, minimum; RBP4, retinol binding protein 4; SD, standard deviation; TTR, transthyretin.